Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Elevated Troponin Levels Associated With Trastuzumab-Related Cardiac Dysfunction

October 26, 2016
By Dave Levitan
Article

In patients with HER2-positive breast cancer undergoing trastuzumab therapy, elevated troponin I or T before the treatment is associated with an increased risk of trastuzumab-related cardiac dysfunction.

In patients with HER2-positive breast cancer undergoing trastuzumab therapy, elevated troponin I or T before the treatment is associated with an increased risk of trastuzumab-related cardiac dysfunction (TRCD), according to a new study.

TRCD is different from anthracycline-induced cardiotoxicity; TRCD is mostly reversible, and is generally assessed by monitoring left ventricular ejection fraction (LVEF). However, this can neither detect early TRCD or predict deterioration of cardiac function, according to study authors led by Evandro de Azambuja, MD, PhD, of the Jules Bordet Institute in Brussels.

The new study tested whether certain cardiac markers might fill that gap. It included 452 patients who were enrolled in the HERA (Herceptin Adjuvant) study, and examined whether troponins I and T along with N­-terminal prohormone of brain natriuretic peptide (NT-proBNP) was associated with cardiac endpoints including significant LVEF drop, congestive heart failure class III or IV, or death due to definite or probable cardiac cause. The results were published online ahead of print in the Journal of Clinical Oncology.

A total of 56 of 412 evaluable patients had elevated troponin I (> 40 ng/L; 13.6%) at baseline, and 101 of 407 had elevated troponin T (> 14 ng/L; 24.8%). These elevations were associated with occurrence of a significant drop in LVEF, for troponin I, the hazard ratio (HR) on a univariate analysis for LVEF drop was 4.52 (95% CI, 2.45–8.35; P < .001); for troponin T, the HR was 3.57 (95% CI, 1.95–6.55; P < .001).

There is no generally accepted cutoff value for elevation of NT-proBNP, so the investigators modeled whether incremental increases in the marker were associated with LVEF drop. For each increase of 1 ng/dL of NT-proBNP, the HR was 1.03 (95% CI, 1.02–1.04; P < .001). They noted that this should be considered clinically meaningful.

Only three patients in the study experienced a cardiac endpoint; one of these had missing baseline marker values, and the other two had increased BNP and troponin levels at baseline.

“Our study represents the largest effort to identify markers for TRCD within the context of a randomized adjuvant trastuzumab trial, confirming that increased troponin I is associated with [increased TRCD risk] in women receiving adjuvant trastuzumab,” the authors concluded, adding that this is the first time elevated troponin T was shown to be associated as well. “Further studies for identification of predictive markers of TRCD are warranted.”

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Related Content
Advertisement

8 A Case Series Exploring Characteristics and Outcomes of Metachronous Primary Breast and Lung Cancer in a Diverse Cohort

8 A Case Series Exploring Characteristics and Outcomes of Metachronous Primary Breast and Lung Cancer in a Diverse Cohort

Keerthana Sureshkumar;Richa Dawar
July 10th 2025
Article


Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.


10 AI as a Bridge: Can ChatGPT Help Patients Understand Their Breast Radiology Reports?

10 AI as a Bridge: Can ChatGPT Help Patients Understand Their Breast Radiology Reports?

Siya Patil;Emily Rooney;Hemal Grover;Christine Chen
July 8th 2025
Article

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.


Survival benefit was observed in heavily pretreated populations, including those who progressed after checkpoint inhibition and antibody drug conjugates.

Bria-IMT Yields Updated Survival Benefit in Metastatic Breast Cancer

Roman Fabbricatore
July 8th 2025
Article

Survival benefit was observed in heavily pretreated populations, including those who progressed after checkpoint inhibition and antibody-drug conjugates.


12 Gut Microbiome Composition and Pathological Complete Response After Chemotherapy in Breast Cancer: Insights From a Pilot Study

12 Gut Microbiome Composition and Pathological Complete Response After Chemotherapy in Breast Cancer: Insights From a Pilot Study

Diana Kantarovich;Olutayo Sogunro;Christopher Umbricht;Catherine E. Klein, MD;James White;Mehran Habibi
July 7th 2025
Article
Related Content
Advertisement

8 A Case Series Exploring Characteristics and Outcomes of Metachronous Primary Breast and Lung Cancer in a Diverse Cohort

8 A Case Series Exploring Characteristics and Outcomes of Metachronous Primary Breast and Lung Cancer in a Diverse Cohort

Keerthana Sureshkumar;Richa Dawar
July 10th 2025
Article


Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.


10 AI as a Bridge: Can ChatGPT Help Patients Understand Their Breast Radiology Reports?

10 AI as a Bridge: Can ChatGPT Help Patients Understand Their Breast Radiology Reports?

Siya Patil;Emily Rooney;Hemal Grover;Christine Chen
July 8th 2025
Article

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.


Survival benefit was observed in heavily pretreated populations, including those who progressed after checkpoint inhibition and antibody drug conjugates.

Bria-IMT Yields Updated Survival Benefit in Metastatic Breast Cancer

Roman Fabbricatore
July 8th 2025
Article

Survival benefit was observed in heavily pretreated populations, including those who progressed after checkpoint inhibition and antibody-drug conjugates.


12 Gut Microbiome Composition and Pathological Complete Response After Chemotherapy in Breast Cancer: Insights From a Pilot Study

12 Gut Microbiome Composition and Pathological Complete Response After Chemotherapy in Breast Cancer: Insights From a Pilot Study

Diana Kantarovich;Olutayo Sogunro;Christopher Umbricht;Catherine E. Klein, MD;James White;Mehran Habibi
July 7th 2025
Article
Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.